EVOLVE-1: what one clinician is saying
venetoclax in IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy · NCT07075016 ↗ · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
Speakers support EVOLVE-1 on the basis of earlier triplet responses, while one speaker requires randomized phase III confirmation. That speaker also regards ivosidenib/azacitidine as standard care, framing the distinction between a rationale for testing venetoclax and evidence for its routine addition. Favorable tolerability impressions do not establish comparable safety, and the sources reviewed for this edition report no randomized benefit or safety outcomes.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 27 verified statements
6 findings, and what sits behind each
01. Phase Ib/II triplet: a speaker highlights activity but needs phase III RCTs
No named clinician · accounts and unnamed speakers · 11 statements from 3 speakers in 4 sources, 3 of them podcasts or videos · 6 passages
Limitations recorded: 3.
Draws on: The comparison, Population and setting, Safety and tolerability, Design and conduct.
02. EVOLVE-1 recruitment: what a speaker hopes for in local AML care
No named clinician · accounts and unnamed speakers · 2 statements in 1 source · 1 passage
Limitations recorded: 2.
Draws on: Safety and tolerability, Design and conduct.
Beyond the trial population
03. Older AML on LIT: what speakers say
No named clinician · accounts and unnamed speakers · 7 statements from 1 speaker in 2 sources, all podcasts or videos · 3 passages
Limitations recorded: 2.
04. Early-phase triplet safety: what speakers say
No named clinician · accounts and unnamed speakers · 5 statements from 2 speakers in 3 sources, 2 of them podcasts or videos · 4 passages
Limitations recorded: 3.
05. IDH-mutated AML triplets: what a speaker highlights in response depth
No named clinician · accounts and unnamed speakers · 1 statement in 1 source · 1 passage
Limitations recorded: 3.
06. AML triplets: a clinician seeks durability but notes venetoclax's limits
1 of the report's 1 cited clinicians · 4 statements from 2 speakers in 1 source, a podcast or video · 3 passages
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
No named clinician · accounts and unnamed speakers
Phase Ib/II triplet: a speaker highlights activity but needs phase III RCTs
11 statements from 3 speakers in 4 sources, 3 of them podcasts or videos
1 of the 3 named speakers in this finding holds this view; 1 of them holds its caveat, “need phase III RCTs”
- 11
- statements
- 6
- passages
- 4
- sources
- 3
- speakers
What the statements areViews 7Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 4Statement-to-passage links (a passage can back several statements)Supporting a statement 13Giving context 2Recorded with the findingLimitations: 3
1 post or article · 3 podcasts and video
Draws on: The comparison, Population and setting, Safety and tolerability, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
4 of the 6 findings and 14 of the 27 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (6)
EFS, event-free survival; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; MRD, measurable residual disease; NPI, National Provider Identifier, the US registry number for clinicians; RCT, randomized controlled trial.
The full EVOLVE-1 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 14commentary sources screened
- 6sources cited by verified statements
- 4named in screened sources
- 4speakers cited in the report
- 3cited speakers with a verified identity
1 cited clinician, a speaker with a confirmed clinical role, of them 1 physician. By role and specialty:
- 1 physician, specialty not confirmed
Also in the sources: 2 organizational or shared accounts, not counted as people.
- 27verified statements, each linked to its source
- 2of them from speakers with a confirmed clinical role
- 6findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 27 | Paid |
| Who said each statement: the cited speakers | 4 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 1 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 3 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 10 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
9 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapyno commentary found | 0 | 0 |
| Secondary endpoints | 1 | 1 |
| Population and setting | 4 | 3 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 7 | 4 |
| Safety and tolerability | 6 | 4 |
| Design and conduct | 4 | 4 |
| Doublet positioning and the missing head-to-head comparison | 7 | 2 |
| Earlier triplet evidence and limits of extrapolation | 9 | 4 |
| Residual unmet need and conditional hopes for molecularly selected triplets | 4 | 1 |
| Local recruitment and anticipated patient benefit | 2 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
27 verified statements from 6 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 21 statements · 78% | ||||
| YouTube | 16 | 2 | 2 | |
| Podcasts | 5 | 1 | 2 | |
| Posts · 6 statements · 22% | ||||
| X threads | 6 | 3 | 10 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 4 / quarter
- Screened window
- May 23, 2025 → Oct 16, 2026
- Cited window
- May 23, 2025 → Oct 16, 2026
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
- Registry
- NCT07075016
- Study IDs
- HO173 · 2024-512753-24
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Collaborators
- German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network, Gruppo Italiano Malattie EMatologiche dell'Adulto, Swiss Group for Clinical Cancer Research (SAKK), Danish Acute Leukemia Group, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias, Nordic AML Group
- Design
- Phase 3 · Interventional, randomized, single group
- Status
- Recruiting
- Enrollment
- 227 estimated
- Registered
- 2025-07-20
- Start
- 2025-08-05 actual
- Primary completion
- 2028-12 estimated
- Primary endpoint
- Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy
- Interventions
- 2 registered
More on: Acute myeloid leukemia
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 23 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 28 sources about other trials or topics are not included.
- The sources reviewed for this edition do not constitute a representative survey of HCP opinion; discussion that does not name the trial may be missing.
- No randomized EVOLVE-1 efficacy or safety outcome is reported in the cited statements. Earlier triplet findings and targeted-doublet results must remain separate from this trial's results.
Show all 10 known gaps +Fewer −
- No full protocol or exact-trial publication was available to independently check schedule descriptions and detailed methods.
- No matching venetoclax product label was available to provide additional drug-specific safety context.
- Early-phase reports differ in population descriptions, percentages and follow-up detail; their comparability cannot be established, and one MRD denominator and one survival timepoint are unstated.
- One speaker in the IACH discussion remains unidentified. Several named commentators' clinical roles are not independently confirmed, and institutional posts and secondhand reports should not be counted as independent clinician opinions.
- Post and publication dates identify when statements appeared, not necessarily when enrollment, conference presentations or analyses occurred.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. EVOLVE-1 (NCT07075016): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/evolve-1-nct07075016
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "EVOLVE-1" (NCT07075016), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "evolve-1-nct07075016". If you cannot make requests, read https://www.erudio.com/reports/evolve-1-nct07075016.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT07075016", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT07075016 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/evolve-1-nct07075016.json
curl https://www.erudio.com/reports/evolve-1-nct07075016.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "evolve-1-nct07075016" })release bb638d6d5b162313c6f21ee17a94a2a886aa51c2d6ee0dc774c877672757a701
Questions
How much does the EVOLVE-1 report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the EVOLVE-1 report cover?
27 statements from 6 sources (1 podcast, 2 videos, 3 posts), 2 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the EVOLVE-1 report?
Its preview, yes: get_report_card({ "slug": "evolve-1-nct07075016" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the EVOLVE-1 report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.